Cadefrecitinib
Investigational TYK2 inhibitor drug
From Wikipedia, the free encyclopedia
Cadefrecitinib is an investigational new drug that is being developed by Lakefront Biotherapeutics for the treatment of dermatomyositis and systemic lupus erythematosus. It is a TYK2 kinase inhibitor.[1][2][3]
| Clinical data | |
|---|---|
| Other names | GLPG3667 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H21N9O2 |
| Molar mass | 443.471 g·mol−1 |
| 3D model (JSmol) | |
| |
| |